School of Medicine


Showing 481-500 of 503 Results

  • William Weis

    William Weis

    Member, Bio-X

    Current Research and Scholarly InterestsOur laboratory studies molecular interactions that underlie the establishment and maintenance of cell and tissue structure. Our principal areas of interest are the architecture and dynamics of intercellular adhesion junctions, signaling pathways that govern cell fate determination, and determinants of cell polarity. Our overall approach is to reconstitute macromolecular assemblies with purified components in order to analyze them using biochemical, biophysical and structural methods.

  • Irving Weissman

    Irving Weissman

    Virginia & D.K. Ludwig Professor of Clinical Investigation in Cancer Research, Professor of Pathology, and of Developmental Biology

    Current Research and Scholarly InterestsStem cell and cancer stem cell biology; development of T and B lymphocytes; cell-surface receptors for oncornaviruses in leukemia. Hematopoietic stem cells; Lymphocyte homing, lymphoma invasiveness and metastasis; order of events from hematopoietic stem cells [HSC] to AML leukemia stem cells and blood diseases, and parallels in other tissues; discovery of tumor and pathogenic cell 'don't eat me' and 'eat me' signals, and translation into therapeutics.

  • Paul Wender

    Paul Wender

    Francis W. Bergstrom Professor and Professor, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsMolecular imaging, therapeutics, drug delivery, drug mode of action, synthesis

  • Wen-Kai Weng, MD, PhD

    Wen-Kai Weng, MD, PhD

    Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology

    Current Research and Scholarly InterestsMy research interest is on immunotherapy (including allogeneic transplant) of cancer. I have studies the mechanism of monoclonal antibody therapy in lymphoma patients and am currently working on designing new strategy to enhance the clinical efficacy of antibody therapy by infusing expanded NK cells. I am also interested in using tumor vaccine along with hematopoietic cell transplant.

  • Marius Wernig

    Marius Wernig

    Professor of Pathology and, by courtesy, of Chemical and Systems Biology

    Current Research and Scholarly InterestsEpigenetic Reprogramming, Direct conversion of fibroblasts into neurons, Pluripotent Stem Cells, Neural Differentiation: implications in development and regenerative medicine

  • Robert West

    Robert West

    Professor of Pathology

    Current Research and Scholarly InterestsRob West, MD, PhD, is a Professor of Pathology at Stanford University Medical Center. He is a clinician scientist with experience in translational genomics research to identify new prognostic and therapeutic markers in cancer. His research focus is on the progression of neoplasia to carcinoma. His lab has developed spatially oriented in situ methods to study archival specimens. He also serves as a surgical pathologist specializing in breast pathology.

  • Monte Winslow

    Monte Winslow

    Associate Professor of Genetics and of Pathology

    Current Research and Scholarly InterestsOur laboratory uses genome-wide methods to uncover alterations that drive cancer progression and metastasis in genetically-engineered mouse models of human cancers. We combine cell-culture based mechanistic studies with our ability to alter pathways of interest during tumor progression in vivo to better understand each step of metastatic spread and to uncover the therapeutic vulnerabilities of advanced cancer cells.

  • John Witte

    John Witte

    Professor of Epidemiology and Population Health, of Biomedical Data Science and, by courtesy, of Genetics

    BioDr. Witte joined the Stanford community in July 2021. In addition to serving as Vice Chair and professor in the Department of Epidemiology & Population Health, and as a professor of Biomedical Data Science and, by courtesy, of Genetics, he will also serve as a member of the Stanford Cancer Institute.

    Dr. Witte is an internationally recognized expert in genetic epidemiology. His scholarly contributions include deciphering the genetic and environmental basis of prostate cancer and developing widely used methods for the genetic epidemiologic study of disease. His prostate cancer work has used comprehensive genome-wide studies of germline genetics, transcriptomics, and somatic genomics to successfully detect novel variants underlying the risk and aggressiveness of this common disease. A key aspect of this work has been distinguishing genetic factors that may drive increased prostate cancer risk and mortality among African American men. Providing an avenue to determine which men are more likely to be diagnosed with clinically relevant prostate cancer and require additional screening or specific treatment can help reduce disparities in disease prevalence and outcomes across populations. Dr. Witte has also developed novel hierarchical and polygenic risk score modeling for undertaking genetic epidemiology studies. These advances significantly improve our ability to detect disease-causing genes and to translate genetic epidemiologic findings into medical practice.

    Dr. Witte has received the Leadership Award from the International Genetic Epidemiology Society (highest award), and the Stephen B. Hulley Award for Excellence in Teaching. His extensive teaching portfolio includes a series of courses in genetic and molecular epidemiology. He has mentored over 50 graduate students and postdoctoral fellows, serves on the executive committees of multiple graduate programs, and has directed a National Institutes of Health funded post-doctoral training program in genetic epidemiology for over 20 years. Recently appointed to the National Cancer Institute Board of Scientific Counselors, Dr. Witte has been continuously supported by the National Institutes of Health.

  • Albert J. Wong, M.D.

    Albert J. Wong, M.D.

    Professor of Neurosurgery

    Current Research and Scholarly InterestsOur goal is to define targets for cancer therapeutics by identifying alterations in signal transduction proteins. We first identified a naturally occurring mutant EGF receptor (EGFRvIII) and then delineated its unique signal transduction pathway. This work led to the identification of Gab1 followed by the discovery that JNK is constitutively active in tumors. We intiated using altered proteins as the target for vaccination, where an EGFRvIII based vaccine appears to be highly effective.

  • Wing Hung Wong

    Wing Hung Wong

    Stephen R. Pierce Family Goldman Sachs Professor of Science and Human Health and Professor of Biomedical Data Science

    Current Research and Scholarly InterestsCurrent interest centers on the application of statistics to biology and medicine. We are particularly interested in questions concerning gene regulation, genome interpretation and their applications to precision medicine.

  • Albert Y. Wu, MD, PhD, FACS

    Albert Y. Wu, MD, PhD, FACS

    Assistant Professor of Ophthalmology

    Current Research and Scholarly InterestsMy translational research focuses on using autologous stem cells to recreate a patient’s ocular tissues for potential transplantation. We are generating tissue from induced pluripotent stem cells to treat limbal stem cell deficiency in patients who are bilaterally blind. By applying my background in molecular and cellular biology, stem cell biology, oculoplastic surgery, I hope to make regenerative medicine a reality for those suffering from orbital and ocular disease.

  • Joseph  C. Wu, MD, PhD

    Joseph C. Wu, MD, PhD

    Director, Stanford Cardiovascular Institute, Simon H. Stertzer, MD, Professor and Professor of Radiology

    Current Research and Scholarly InterestsDrug discovery, drug screening, and disease modeling using iPSC.

  • Joy Wu

    Joy Wu

    Associate Professor of Medicine (Endocrinology)

    Current Research and Scholarly InterestsMy laboratory focuses on the pathways that regulate the differentiation of mesenchymal stem cells into the osteoblast and adipocyte lineages. We are also studying the role of osteoblasts in the hematopoietic and cancer niches in the bone marrow microenvironment.

  • Joanna Wysocka

    Joanna Wysocka

    Lorry Lokey Professor and Professor of Developmental Biology

    Current Research and Scholarly InterestsThe precise and robust regulation of gene expression is a cornerstone for complex biological life. Research in our laboratory is focused on understanding how regulatory information encoded by the genome is integrated with the transcriptional machinery and chromatin context to allow for emergence of form and function during human embryogenesis and evolution, and how perturbations in this process lead to disease.

  • Lei Xing

    Lei Xing

    Jacob Haimson and Sarah S. Donaldson Professor and Professor, by courtesy, of Electrical Engineering

    Current Research and Scholarly Interestsartificial intelligence in medicine, medical imaging, Image-guided intervention, molecular imaging, biology guided radiation therapy (BGRT), treatment plan optimization

  • Jiangbin Ye

    Jiangbin Ye

    Assistant Professor of Radiation Oncology

    Current Research and Scholarly InterestsOne hallmark of cancer is that malignant cells modulate metabolic pathways to promote cancer progression. My professional interest is to investigate the causes and consequences of the abnormal metabolic phenotypes of cancer cells in response to microenvironmental stresses such as hypoxia and nutrient deprivation, with the prospect that therapeutic approaches might be developed to target these metabolic pathways to improve cancer treatment.

  • Bo Yu, MD

    Bo Yu, MD

    Assistant Professor of Obstetrics and Gynecology (Reproductive Endocrinology and Infertility)

    Current Research and Scholarly InterestsDr. Yu’s lab is interested in ovarian physiology and pathology, as well as assisted reproductive technologies (ART).

  • Lisa Zaba, MD, PhD

    Lisa Zaba, MD, PhD

    Associate Professor of Dermatology

    BioLisa Zaba M.D. Ph.D., is an Associate Professor of Dermatology, and Director of the Merkel cell carcinoma (MCC) multi-disciplinary clinic and member of the supportive oncodermatology group at the Stanford Cancer Center. She runs a lab focusing on the immunology of MCC and the treatment and prognostic implications of immune checkpoint inhibitor and targeted therapy rashes. Dr. Zaba completed medical school at Cornell University, PhD in immunology at Rockefeller University, Residency and Post-Doc at Stanford University in 2013.